Who is sponsoring NCT05361330?

NCT05361330 is sponsored by Peking University.

What drugs are being tested in NCT05361330?

Interventions in NCT05361330: Shuganjieyu capsule, Fluoxetine.

What condition does NCT05361330 study?

NCT05361330 studies Outpatients / Inpatients With Depression.

Is NCT05361330 still recruiting?

NCT05361330 is currently status unknown. Last updated 17 May 2022.

Last reviewed 2022-05-17 · How we verify

NCT05361330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter Clinical Study on Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression

Status unknown NA Last updated 17 May 2022

What this trial tests

NA trial testing Shuganjieyu capsule in Outpatients / Inpatients With Depression in 160 participants. Status unknown.

Timeline

30 May 2022

Primary endpoint
30 April 2023

30 September 2023

Quick facts

Lead sponsor	Peking University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	160
Start date	30 May 2022
Primary completion	30 April 2023
Estimated completion	30 September 2023
Sites	3 locations across China

Drugs / interventions tested

Shuganjieyu capsule — full drug profile →
Fluoxetine (fluoxetine) — full drug profile →

Conditions studied

Outpatients / Inpatients With Depression — all drugs for Outpatients / Inpatients With Depression →

Sponsor

Peking University

Who can join

Adults 18 to 65, any sex, with Outpatients / Inpatients With Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study mainly evaluates the efficacy and safety of Shuganjieyu capsule combined with Fluoxetine as well as the Fluoxetine monotherapy for the treatment of depression in the basic study, and also explores the efficacy for the extended study period as well as the efficacy and safety for the full trial period (basic study period and extended study period).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Multicentre Clinical Trial Protocol of Shuganjieyu Capsules Combined With Fluoxetine in the Treatment of Depression.
Li JT, Liao XM, Zhu LL, Yao ZJ, et al · · 2025 · cited 1× · PMID 40525052 · DOI 10.7759/cureus.84280

Verify or expand the search:

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05361330 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 17 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05361330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing